Weiss Ratings Reiterates Sell (E+) Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

Weiss Ratings reiterated their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTPFree Report) in a research note published on Friday morning,Weiss Ratings reports.

SXTP has been the topic of a number of other reports. HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, March 28th. Wall Street Zen cut 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, June 14th. Finally, Ascendiant Capital Markets upped their price objective on 60 Degrees Pharmaceuticals from $5.80 to $7.00 and gave the company a “buy” rating in a research report on Monday, June 2nd.

Check Out Our Latest Stock Analysis on 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Price Performance

Shares of SXTP stock opened at $2.30 on Friday. 60 Degrees Pharmaceuticals has a 1 year low of $1.41 and a 1 year high of $35.99. The stock’s 50 day simple moving average is $2.47 and its two-hundred day simple moving average is $3.28. The company has a market cap of $3.38 million, a PE ratio of -0.05 and a beta of 2.88.

60 Degrees Pharmaceuticals (NASDAQ:SXTPGet Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.25). The business had revenue of $0.18 million during the quarter, compared to analyst estimates of $0.15 million. Equities research analysts expect that 60 Degrees Pharmaceuticals will post -5.09 EPS for the current year.

About 60 Degrees Pharmaceuticals

(Get Free Report)

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.

Recommended Stories

Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.